Augmenting antidepressant treatment with the dopamine D2/D3 receptor agonist pramipexole led to improvement in depressive symptoms relative to placebo at 12 weeks in patients with treatment-resistant depression, a randomized trial has found. Treatment discontinuation due to adverse events was more prevalent in the pramipexole group, investigators reported. Study results were published online June 29, 2025, in Lancet Psychiatry.
A cohort study using Swedish national data has found that while use of medication treatments for attention-deficit hyperactivity disorder (ADHD) consistently reduced risk of self-harm, unintentional injury, and other adverse outcomes, these associations weakened in later years of the study. Investigators theorized that higher prescribing rates over time incorporated more individuals with less severe symptoms. Study results were published online June 25, 2025, in JAMA Psychiatry.
Paroxetine immediate release (generic) Paxil (brand)
Recent research findings have provided increasing evidence of a “gut-brain axis” that facilitates “communication” between the gut microbiome and the brain. For example, studies have suggested differences in gut flora composition and fecal microbiota in patients with major depressive disorder when compared with healthy controls (Cryan et al., 2019). Despite the increasing volume of data, and the well-known fact that antibiotics disrupt healthy gut flora, few studies have addressed the potential modulating effect of antibiotic exposure on mental health, including depressive illness.
Use of glucagon-like peptide 1 (GLP-1) receptor agonists in patients with diabetes and/or obesity did not increase risk of psychiatric adverse effects or worsening depressive symptoms, a systematic review and meta-analysis has found. Use of GLP-1s in these populations also improved several quality-of-life outcomes. Results of the review and meta-analysis were published online May 14, 2025, in JAMA Psychiatry.
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：